Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R F Schlenk

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Leukemia|July 30, 2003
Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trialR F Schlenk, A Benner, F Hartmann, et al.
Leukemia|August 10, 2011
Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemiaF Damm, T Bunke, F Thol, et al.
Leukemia|April 22, 2005
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemiaR F Schlenk, U Germing, F Hartmann, et al.
Leukemia|October 25, 2016
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosisR F Schlenk, F Stegelmann, A Reiter, et al.
Scientific Reports|September 8, 2023
Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemiaR F Schlenk, D Weber, J Krzykalla, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patientsB C Köhler, G M Haag, L Le Cornet, et al.
Leukemia|February 1, 2017
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failureM Wattad, D Weber, K Döhner, et al.
Leukemia|September 24, 2004
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemiaR F Schlenk, S Fröhling, F Hartmann, et al.
Leukemia|June 24, 2017
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemiaV I Gaidzik, D Weber, P Paschka, et al.
Leukemia|May 4, 2016
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic featuresV I Gaidzik, V Teleanu, E Papaemmanuil, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Leukemia|July 30, 2003
Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trialR F Schlenk, A Benner, F Hartmann, et al.
Leukemia|August 10, 2011
Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemiaF Damm, T Bunke, F Thol, et al.
Leukemia|April 22, 2005
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemiaR F Schlenk, U Germing, F Hartmann, et al.
Leukemia|October 25, 2016
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosisR F Schlenk, F Stegelmann, A Reiter, et al.
Scientific Reports|September 8, 2023
Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemiaR F Schlenk, D Weber, J Krzykalla, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patientsB C Köhler, G M Haag, L Le Cornet, et al.
Leukemia|February 1, 2017
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failureM Wattad, D Weber, K Döhner, et al.
Leukemia|September 24, 2004
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemiaR F Schlenk, S Fröhling, F Hartmann, et al.
Leukemia|June 24, 2017
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemiaV I Gaidzik, D Weber, P Paschka, et al.
Leukemia|May 4, 2016
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic featuresV I Gaidzik, V Teleanu, E Papaemmanuil, et al.
Pageof 4